The 19th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)

Coming Soon...

GHS 2023

JOHN C. MARTIN TRIBUTE (10:45 - 11:00)

Michael Manns

Germany

Public Health 4

Simplified approaches for screening and diagnosis of viral hepatitis (8:30 - 10:50)

Moderators:

Imam Waked

Egypt

Simplified approaches for HCV screening and diagnosis (8:30 – 8:50) + Q&A (8:50 – 8:55)

Simplified approaches for HBV/HDV screening and diagnosis (8:55 – 9:15) + Q&A (9:15 – 9:20)

Dried Blood Spot (Dbs): A New Tool For Screening, Diagnosis And Monitoring Hepatitis D Virus (Hdv) Infection (9:20 – 9:30) + Q&A (9:30 – 9:35)

Rola Matar

Treatment Eligibilty And Performance Of The Who Treatment Criteria In Chronic Hepatitis B Patients In Tanzania (9:35 – 9:45) + Q&A (9:45 – 9:50)

Naveeda Adam

A National Program To Scale-Up Decentralized Hepatitis C Virus Point-Of-Care Testing And Treatment In Australia (9:50 – 10:00) + Q&A (10:00 – 10:05)

Effectiveness Of Reflex Hcv Viral Load Sample Collection In Improving Turn-Around Time For Hcv Diagnostics In Nasarawa State Nigeria (10:05 – 10:15) + Q&A (10:15 – 10:20)

Chukwuemeka Agwuocha

Acceptability And Usability Of Oral Fluid Hcv Self-Testing For Hepatitis C Testing: A Systematic Review (10:20 – 10:30) + Q&A (10:30 – 10:35)

Samara Luiza Silva

Combined Covid-19 Vaccination And Hepatitis C Virus Screening Intervention In Marginalised Populations In Spain (10:35 – 10:45) + Q&A (10:45 – 10:50)

Public Health 2

Global epidemiology of HBV/HDV infections (16:30 - 18:35)

Moderators:

Olufunmilayo Lesi

Nigeria

Global epidemiology of HBV infection (16:30 – 16:50) + Q&A (16:50 – 16:55)

Global epidemiology of HDV infection (16:55 – 17:15) + Q&A (17:15 – 17:20)


The Burden Of Hepatitis B Virus (Hbv) Infection In Children And Women Of Reproductive Age In Nigeria, 2018 (17:20 – 17:30) + Q&A (17:30 – 17:35)

Annemarie Wasley

Clinical Characteristics And Outcomes Of Patients With Cirrhosis And Hepatocellular Carcinoma In The Gambia, West Africa (17:35 – 17:45) + Q&A (17:45 – 17:50)

Gibril Ndow

Updated Prevalence Of Chronic Hepatitis B And Hepatitis Delta Infection Among Foreign-Born Individuals In The United States In 2021 (17:50 – 18:00) + Q&A (18:00 – 18:05)

Robert Wong

National Prevalence And Risk Factors Of Hepatitis Delta Virus Infection In Hbsag Positive Subjects In Cameroon, Central Africa (18:05 – 18:15) + Q&A (18:15 – 18:20)

Richard Njouom

High Molecular Diversity And Remarkable Geographical Distribution Of Hepatitis Delta Virus Strains, That Are Spreading In Cameroon (18:20 – 18:30) + Q&A (18:30 – 18:35)

Segolene Brichler

Basic 2 + 4

Hepatitis immunology (16:30 - 18:40)

Moderators:

Markus Heim

Switzerland

Matteo Ianacone

Italy

Hélène Strick-Marchand

France

Immunological phenotyping of HBV infections (16:30 – 16:50) + Q&A (16:50 – 16:55)

Liver compartmentalization of anti-HBV immune responses (16:55 – 17:15) + Q&A (17:15 – 17:20)

The Development Of A Pan-Genotypic Prophylactic Viral Vectored T Cell Vaccine Against Hepatitis C Virus (17:20 – 17:30) + Q&A (17:30 – 17:35)

Rebecca India Strain

Innate immune responses against HBV and HCV (17:35 – 17:55) + Q&A (17:55 – 18:00)

Adaptive immune responses against HCV (18:00 – 18:20) + Q&A (18:20 – 18:25)

Maike Hofmann

University Medical Center Freiburg Germany

Ex Vivo Immunological Assays Have The Potential To Predict Response To Pd-1 Targeting Therapies In Chronic Hepatitis B Patients (18:25 – 18:35) + Q&A (18:35 – 18:40)

Clinical 12

New developments in liver pathogen detection and discovery (16:30 - 18:20)

Moderators:

Gaston Picchio

USA

Metagenomics for pathogen diagnosis and discovery (16:30 – 16:50) + Q&A (16:50 – 16:55)

Acute severe hepatitis of unknown origin in children (16:55 – 17:15) + Q&A (17:15 – 17:20)

A Novel Technology For Diagnosis Of Hcv Viremia Using Thermo-Sensitive Smart Polymer: Pilot Study Of A Point Of Care Test Of Hcv Compared To Polymerase Chain Reaction Test (Pcr) (17:20 – 17:30) + Q&A (17:30 – 17:35)

Riham Soliman

Innovative Approach Using Clinical Metagenomics For The Diagnosis Of Non-Elucidated Liver Diseases (17:35 – 17:45) + Q&A (17:45 – 17:50)

Anna Sessa

Acute Hepatitis Of Unknown Etiology (Ahua) In Israeli
Children: Human Herpesvirus 6 (Hhv6) As A Possible Trigger For The Disease (17:50 – 18:00) + Q&A (18:00 – 18:05)

Yael Gozlan

Severe Acute Hepatitis Of Unknown Etiology Presenting As Acute Liver Failure In Children: Outcomes From The Liver Intensive Care Unit (18:05 – 18:15) + Q&A (18:15 – 18:20)

Bikrant Biharilal Raghuvanshi

Debate 1

Public Health (14:00 - 16:00)

Chairs:

Niklas Luhmann

Switzerland

Post-COVID relaunch of HCV testing/treatment (14:00 – 14:30)

Improving screening and linkage-to-care in viral hepatitis B and C (14:30 – 15:00)

Public health interventions and awareness in NAFLD/NASH
(15:00 – 15:30)

Cyrielle Caussy

France

Engaging policy makers and patient advocacy groups in liver disease (15:30 – 16:00)

Marko Korenjak

Slovenia

Clinical 2

Difficult-to-treat HCV patients (14:00 - 16:00)

Moderators:

Geoffrey Dusheiko

UK

Jia-Horng Kao

National Taiwan University Hospital Taiwan

Unusual HCV genotypes/subtypes (14:00 – 14:20) + Q&A (14:20 – 14:25)

Difficult-to-cure HCV liver diseases (14:25 – 14:45) + Q&A (14:45 – 14:50)

Glecaprevir/Pibrentasvir Is Safe And Effective In Italian Patients With Chronic Hepatitis C Aged 75 Years Or Older: A Multicenter Study (14:50 – 15:00) + Q&A (15:00 – 15:05)

Nicola Pugliese

Introducing Affordable, Generic Second-Line Treatment For Hepatitis C Elimination In Rwanda: Preliminary Results (15:05 – 15:15) + Q&A (15:15 – 15:20)

Peter Barebwanuwe

Janvier Serumondo

Efficacity Of Two Last-Generation Daa In Infrequent Hepatitis C Genotypes/Subtypes: Real-World Data From The Centre Hospitalier De L’universite De Montreal (15:20 – 15:30) + Q&A (15:30 – 15:35)

Isaac Ruiz

Real-Life Study Of Resistance-Associated Substitutions To Ns5a And Ns5b Inhibitors In Hcv Infected Patients From Argentina (15:35 – 15:45) + Q&A (15:45 – 15:50)

Maria Laura Minassian

EASL-AASLD Joint Symposium 2

Disparities in Liver Cancer (14:00 - 16:00)

Moderators:

AASLD

EASL

Jean-Charles Nault

Avicenne Hospital, APHP France

PART I

Introductions
(14:00 – 14:05)

Disparities in implementation of screening guidelines (14:05 – 14:25) 

EASL

Manon Allaire

Pitié Salpetrière Hospital France

Disparities and treatment outcomes (14:25 – 14:45)

AASLD

Michael E. DeBakey

VA Medical Center USA

Q&A / Joint Panel EASL & AASLD (14:45 – 15:05)

PART II

HCV Screening in underserved cohorts at high risk for HCC (15:05 – 15:25)

AASLD

Impact of social determinants of health on HCC outcomes (15:25 – 15:45)

EASL

Q&A / Joint Panel AASLD & EASL (15:45 – 16:00)

Basic 6

NASH targets for new therapies (14:15 - 15:50)

Moderators:

Mathias Heikenwalder

Germany

Cyrielle Caussy

France

Molecular targets for NASH therapy
(14:15 – 14:35) + Q&A (14:35 – 14:40)

Mathias Heikenwalder

Germany

Preclinical assessment of NASH compounds (14:40 – 15:00) + Q&A (15:00 – 15:05)

Arun Sanyal

Virginia Commonwealth University United States

Dyrk1b Induces Fatty Liver Disease And Its Disruption Is Protective Against Liver Steatohepatitis And Liver Fibrosis (15:05 – 15:15) + Q&A (15:15 – 15:20)

Arya Mani

The Ccaat/Enhancer-Binding Protein Beta – Serpinb3 Axis Inhibition As A Novel Strategy For Non-Alcoholic Steatohepatitis Treatment (15:20 – 15:30) + Q&A (15:30 – 15:35)

Andrea Martini

Late-breaker abstract: Bone Marrow Monocytes Sustain Nk Cell Development And Survival During Non-Alcoholic Steatohepatitis (Nash) (15:35 – 15:45) + Q&A (15:45 – 15:50)

Elsa Bourayou

PLENARY 2

Public health interventions in liver diseases (11:00 - 13:00)

Moderators:

Public health tools to eliminate viral hepatitis (11:00 – 11:25) + Q&A (11:25 – 11:30)

Global achievements and failures in viral hepatitis elimination (11:30 – 11:55) + Q&A (11:55 – 12:00)

Meg Doherty

WHO Switzerland

HCV elimination in Egypt: a success story (12:00 – 12:25) + Q&A (12:25 – 12:30)

Public health interventions to eliminate NAFLD/NASH (12:30 – 12:55) + Q&A (12:55 – 13:00)

Clinical 11

New biomarkers for liver diseases (8:30 - 10:35)

Moderators:

Alina Allen

USA

Jérôme Boursier

France

New biomarkers for fibrosis assessment (8:30 – 8:50) + Q&A (8:50 – 8:55)

New biomarkers for HCC risk prediction (8:55 – 9:15) + Q&A (9:15 – 9:20)

Circulating Hbv Rna Correlates With Intrahepatic Covalently Closed Circular Dna (Cccdna) Transcriptional Activity In Untreated And Nuc-Treated Chronic Hepatitis B (Chb) Patients (9:20 – 9:30) + Q&A (9:30 – 9:35)

Development And Clinical Utility Of High-Throughput Hbcag-Specific Immunoassays For The Management Of Hbv Therapies (9:35 – 9:45) + Q&A (9:45 – 9:50)

Rene Geissler

Hepatitis B Core Related Antigen (Hbcrag), Not As Good As It Seems?: A Critique And Systematic Review (9:50 – 10:00) + Q&A (10:00 – 10:05)

The Use Of Limax In Predicting Clinically Relevant Milestones In Chronic Liver Disease Of Different Aetiologies (10:05 – 10:15) + Q&A (10:15 – 10:20)

Anushri Joshi

Late-breaker abstract: Circulating Fibroblast Activation Protein Alpha (Fap) And Dipeptidyl Peptidase 4 (Dpp4) As Biomarkers For Fibrosis And Steatosis
(10:20 – 10:30) + Q&A (10:30 – 10:35)

Mark D Gorrell

Basic 7

HCC targets for new therapies (8:30 - 10:05)

Moderators:

Chiara Raggi

Italy

Molecular targets for HCC therapy
(8:30 – 8:50) + Q&A (8:50 – 8:55)

Immunological targets for HCC therapy (8:55 – 9:15) + Q&A (9:15 – 9:20) 

Expression Of The Axonal Guidance Cue Netrin-1 Associates With Neoneurogenesis Of Druggable Cholinergic Orientation And Aggressive Hcc Features (9:20 – 9:30) + Q&A (9:30 – 9:35)

Charlotte A. Hernandez

Enhancer Of Zeste Homolog 2 (Ezh2) And O-Glcnac Transferase (Ogt) Modulate Cell Cycle And Cancer-Associated Pathways In Hepatocellular Carcinoma (9:35 – 9:45) + Q&A (9:45 – 9:50)

Margot Thirion

Targeting Cd63 As A Novel Fibrogenic Immune Target For The Treatment Of Hepatocellular Carcinoma And The Reversion Of Hepatic Fibrosis (9:50 – 10:00) + Q&A (10:00 – 10:05)

Cristabelle De Souza

Gerlinde Wernig

EASL-AASLD Joint Symposium 1

The Impact of social media in Liver Disease Research and Education – Is it time to embrace this more widely? (8:30 - 10:30)

Moderators:

What do I gain from my involvement in social media – the viewpoint of a senior academic (8:30 – 8:50)

AASLD

Medical Education Opportunities in social media – Tweetorials, journal clubs and more (8:50 – 9:10)

AASLD

An Editor’s View on the role of social media in the dissemination of research findings (9:10 – 9:30)

EASL

Jean-Charles Nault

Avicenne Hospital, APHP France

Medical social media and the ‘Echo Chamber’ – the good, the bad and the ugly (9:30 – 9:50)

EASL

Walter Quattrociocchi

Italy

Debate: HCPs have a moral obligation to be involved in social media to counteract disinformation (9:50 – 10:05)

Panel Discussion (10:05 – 10:20)

Basic 5

HBV/HDV treatment targets (8:30 - 10:35)

Moderators:

Lena Allweiss

Germany

David Durantel

France

Targeting HBV capsids for therapy (8:30 – 8:50) + Q&A (8:50 – 8:55)

Targeting HBV RNAs for therapy (8:55 – 9:15) + Q&A (9:15 – 9:20)

Class A Capsid Assembly Modulators Induce Cell Death Through Hbv Core Protein Aggregation And Potentially Activate The Innate Immune Response (9:20 – 9:30) + Q&A (9:30 – 9:35)

Valerio Taverniti

A Gene Editing Approach For Chronic Hepatitis B: Elimination Of Hepatitis B Virus In Vivo By Targeting Cccdna And Integrated Viral Genomes With A Sequence-Specific Arcus Nuclease (9:35 – 9:45) + Q&A (9:45 – 9:50)

Cassandra Gorsuch

The Tlr8 Agonist Selgantolimod Modulates Kupffer Cell Differentiation Status And Indirectly Impairs Hbv Entry Into Hepatocytes Via An Il-6-Dependent Mechanism (9:50 – 10:00) + Q&A (10:00 – 10:05)

Armando Andres Roca Suarez

Therapeutic Vaccination For Chronic Hepatitis B Using Adjuvant-Loaded Particulate Hepatitis B Core Antigen (10:05 – 10:15) + Q&A (10:15 – 10:20)

Jinpeng Su

Fxr Agonists Alone Or In Combination With Ifna Inhibit Hbv Replication And Hdv Propagation In Functional Hepatocytes (10:20 – 10:30) + Q&A (10:30 – 10:35)

Romain Barnault

Clinical 3

New strategies with approved HBV treatments (16:30 - 18:35)

Moderators:

Xin-Xin Zhang

China

Stoppings NUC strategies (16:30 – 16:50) + Q&A (16:50 – 16:55)

Interferon add-on/switch strategies (16:55 – 17:15) + Q&A (17:15 – 17:20)

Switching Tenofovir Disoproxil Fumarate (Tdf) To Tenofovir Alafenamide Fumarate (Taf) In Hepatitis B/Hiv Co-Infection: A Feasibility Study (17:20 – 17:30) + Q&A (17:30 – 17:35)

James Lok

Tenofovir Disoproxil Fumarate (Tdf) Versus Tenofovir Alafenamide (Taf) Or Tdf/Emtricitabine (Tdf/Ftc) To Treat Hepatitis B: Meta-Analysis Of 2914 Patients In 11 Randomised Clinical Trials (17:35 – 17:45) + Q&A (17:45 – 17:50)

Andrew Hill

Hepatitis B Surface Antigen Kinetics During And After Nucleos(T)Ide Analogues Described By Mathematical Modeling (17:50 – 18:00) + Q&A (18:00 – 18:05)

Piero Colombatto

Early Off-Treatment Kinetics Of Viral And Host Biomarkers After Discontinuation Of Nucleos(T)Ide Analogues Among Chronic Hepatitis B Patients (Retract-B Study) (18:05 – 18:15) + Q&A (18:15 – 18:20)

Grishma Hirode

The Long-Term Prognosis And The Need For Histologic Assessment In Chronic Hepatitis B In Serological Immune-Tolerant Phase (18:20 – 18:30) + Q&A (18:30 – 18:35)

Jeong-Ju Yoo

Clinical 1

Applications of artificial intelligence in liver disease management (16:30 - 17:50)

Moderators:

Valérie Paradis

France

Pascal Roy

France

Data sciences in viral hepatitis (16:30 – 16:50) + Q&A (16:50 – 16:55)

Artificial intelligence for liver cancer management (16:55 – 17:15) + Q&A (17:15 – 17:20)

Prediction Of Hbv-Related Cirrhosis Complications With Machine Learning Algorithms Using Electronic Health Records (17:20 – 17:30) + Q&A (17:30 – 17:35)

Vivian Chia-Rong Hsieh

Spatial Transcriptomics Reveals Widespread Intrahepatic Hepatitis B Virus Integration In Chronic Infected Patients (17:35 – 17:45) + Q&A (17:45 – 17:50)

Xiaoqi Yu

Public Health 1

Epidemiology of HCV in resource-limited countries (16:30 - 18:20)

Moderators:

Tarik Asselah

France

Erika Duffell

Sweden

Prevalence of HCV infection in resource-limited countries (16:30 – 16:50) + Q&A (16:50 – 16:55)

Dynamics of the HCV epidemic in resource-limited countries (16:55 – 17:15) + Q&A (17:15 – 17:20)

High Hcv Incidence Is Associated With Social And Spatial Network Structures Among People Who Inject Drugs In New Delhi (17:20 – 17:30) + Q&A (17:30 – 17:35)

Steven J. Clipman

An Unexpectedly High Hepatitis C Virus Prevalence In Southern Laos Led To The Identification Of Risk Practices And Suggested That Extensive Testing And Treatment Are Required (17:35 – 17:45) + Q&A (17:45 – 17:50)

Judith M Hübschen

Rising Trend Of Symptomatic Infections Due To Hepatitis A Virus Infection In Adolescent And Adult Age Group: An Observational Study From A Tertiary Care Liver Institute In India (17:50 – 18:00) + Q&A (18:00 – 18:05)

Jasmine Samal

Late-breaker abstract: Understanding Hepatitis C Reinfection Rates And Factors Associated With Hcv Infection In New Jersey, USA (18:05 – 18:15) + Q&A (18:15 – 18:20)

Corey L DeStefano

Jihad Slim

Basic 1

HCV/flavivirus virology (16:30 - 18:35)

Moderators:

Mirjam Zeisel

France

Naglaa Shoukry

Canada

What did HCV teach us on flavivirus virology (16:30 – 16:50) + Q&A (16:50 – 16:55)

HCV entry: lessons learnt for other viruses (16:55 – 17:15) + Q&A (17:15 – 17:20)

A Step-Wise Adaptation Of Hepatitis C Virus Leads To A High Rate Of Infection In Primary Mouse Hepatocytes (17:20 – 17:30) + Q&A (17:30 – 17:35)

Julie Sheldon

Evaluation Of Hepatitis C Virus Transmitted/Founder Variants Obtained From Observed Hcv Infection Through Lung Transplantation From Hcv-Infected Donors To Uninfected Recipients (17:35 – 17:45) + Q&A (17:45 – 17:50)

Nahla Fadlelmawla

Demonstration Of Hcv Rna Methylation In Clinical Isolates And Comparison With Cell Culture-Derived Virus (17:50 – 18:00) + Q&A (18:00 – 18:05)

Nahla Fadlelmawla

Comparison Of Hav And Hcv Infections In Vivo And In Vitro Reveals Distinct Patterns Of Innate Immune Evasion And Activation (18:05 – 18:15) + Q&A (18:15 – 18:20)

Ombretta Colasanti

Virological Characterization Of Treatment Failures And Retreatment Outcomes In Patients Infected With “Unusual” Hcv Genotype 1 Subtypes (18:20 – 18:30) + Q&A (18:30 – 18:35)

Erwan Vo Quang

Late-breaker abstract: Intracellular “In Silico Microscopes” – Fully 3d Spatial Hepatitis C Virus Replication Model Simulations (18:35 – 18:45) + Q&A (18:45 – 18:50)

PLENARY 1

Innovations in liver disease therapy: present and future

Moderators:

Innovations in direct-acting antiviral therapies (14:00 – 14:25) + Q&A (14:25 – 14:30)

Innovations in antiviral immunotherapy (14:30 – 14:55) + Q&A (14:55 – 15:00)

Innovations in liver fibrosis and NASH therapy (15:00 – 15:25) + Q&A (15:25 – 15:30)

Arun Sanyal

Virginia Commonwealth University United States

Innovations in hepatocellular carcinoma therapy (15:30 – 15:55) + Q&A (15:55 – 16:00)

Clinical 7

NAFLD/NASH therapeutic developments (16:30 - 17:50)

Moderators:

Clinical Trial dndpoints in NASH cirrhosis (16:30 – 16:50) + Q&A (16:50 – 16:55)

New treatment approaches for NAFLD/NASH (16:55 – 17:15) + Q&A (17:15 – 17:20)

Obesity Is Associated With A Late-Stage Hepatocellular Carcinoma At Diagnosis Despite Adequate Ultrasound Surveillance (17:20 – 17:30) + Q&A (17:30 – 17:35)

Hooman Farhang Zangneh

Efficacy And Safety Of Alxn1840 Versus Standard Of Care In Wilson Disease: Primary Results From An Ongoing Phase 3, Randomized, Controlled, Rater-Blinded Trial (17:35 – 17:45) + Q&A (17:45 – 17:50)

Aftab Ala

Clinical 4

New HBV drug clinical developments (8:00 - 10:20)

Moderators:

Marc Bourlière

France

Direct-acting antiviral HBV drugs in development (8:00 – 8:20) + Q&A (8:20 – 8:25)

Anti-HBV immunotherapies and combination perspectives (8:25 – 8:45) + Q&A (8:45 – 8:50)

Late-breaker abstract: Mechanistic Pk/Pd Modeling And Simulation Of Bepirovirsen Pk, Hbsag And Alt Changes From Phase 2b Study To Inform Phase 3 Study Design And Dose Selection: B-Clear Study (8:50 – 9:00) + Q&A (9:00 – 9:05)

Nadia Noormohamed

Late-breaker abstract: Pharmacokinetics And Safety Of Single-Dose Bepirovirsen In Adults With Moderate Hepatic Impairment And Healthy Matched Controls (B-Assured) (9:05 – 9:15) + Q&A (9:15 – 9:20)

Nadia Noormohamed

Late-breaker abstract: 48 Weeks Of Ab-729 + Nucleos(T)Ide Analogue (Na) Therapy Results In Profound, Sustained Hbsag Declines In Both Hbeag+ And Hbeag- Subjects Which Are Maintained In Hbeag- Subjects Who Have Discontinued All Therapy (9:20 – 9:30) + Q&A (9:30 – 9:35)

Late-breaker abstract: Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB) (9:35 – 9:45) + Q&A (9:45 – 9:50)

Late-breaker abstract: 3-Antigen Hbv Vaccine, With Pre-S1, Pre-S2 And S Antigens, Induces A Higher And More Durable Immune Response Compared To 1-Antigen Hbv Vaccine (9:50 – 10:00) + Q&A (10:00 – 10:05)

Lutz Maubach

Late-breaker abstract: Under-Representation Of Who Africa Region In Hbv Clinical Trials: The Field Advances, But In Which Direction? (10:05 – 10:15) + Q&A (10:15 – 10:20)

Marion Delphin

WHO SYMPOSIUM

Viral Hepatitis Elimination What’s new, what’s next, what’s missing in WHO guidance (8:30 - 10:30)

Moderators:

Meg Doherty

WHO Switzerland

Setting the scene-what’s new – evolving global perspective and hepatitis strategy (8:30 – 8:40) + Q&A (8:40 – 8:45)

Meg Doherty

WHO Switzerland

Next steps for validating progress of the hepatitis response & Path-to-Elimination (PTE) (8:45 – 8:55) + Q&A (8:55 – 9:00)

What’s new and what’s next- Simplified service delivery for adults & children with hepatitis B and C (9:00 – 9:10) + Q&A (9:10 – 9:15)

Reaching hepatitis elimination in key populations and PWID (9:15 – 9:25) + Q&A (9:25 – 9:30)

Niklas Luhmann

Switzerland

Towards 2030 elimination: Data for person centered care, hepatitis cascade and mortality impact (9:30 – 9:40) + Q&A (9:40 – 9:45)

Catherine de Martel

Diana Faini

Facilitated panel discussion – Looking ahead to 2030: What’s missing (9:45 – 10:15)

Country perspectives – HCV self-testing: Saeed Hamid (Pakistan)
Implementing partner: Oriel Fernandez (CHAI)
Community perspectives: Su Wang, World Hepatitis Alliance (WHA)
The financing gap: Finn Jarle Rode/Maria Salazar, (The Hepatitis Fund (THF))
Coordinated public health responses from Countries: John Ward (CGHE)
Data to measure and drive progress: Homie Razavi (CDA Foundation)

Closing reflections and way forward by Margaret Hellard (10:15 – 10:30)

Public Health 5

Reaching vulnerable populations for viral hepatitis elimination (8:30 - 10:50)

Moderators:

Manal Al-Sayed

Egypt

Reaching PWID/prison populations for viral hepatitis elimination (8:30 – 8:50) + Q&A (8:50 – 8:55)

Reaching migrant populations for viral hepatitis elimination (8:55 – 9:15) + Q&A (9:15 – 9:20)

Impact Of Hcv Testing And Treatment Services On Hcv Transmission Among Men Who Have Sex With Men And Who Inject Drugs In San Francisco: A Modelling Analysis
(9:20 – 9:30) + Q&A (9:30 – 9:35)

Adelina Artenie

Engagement In Hepatitis C Screening And Treatment Among Pregnant And Postpartum Individuals In Ontario, Canada: A Population-Based Retrospective Cohort Study (9:35 – 9:45) + Q&A (9:45 – 9:50)

Andrew Bryan Mendlowitz

A Community-Based Intervention To Reduce Missed Opportunities In Primary Care For Viral Hepatitis Screening Among At-Risk African Migrants In Catalonia, Spain (9:50 – 10:00) + Q&A (10:00 – 10:05)

Camila A Picchio

Characterizing Operational Models Of Hepatitis B And C Care For Refugee Populations: Results Of A Systematic Review (10:05 – 10:15) + Q&A (10:15 – 10:20)

Ankeeta Saseetharran

Putting People At The Centre: Protocol For Patient Journey Mapping Of Viral Hepatitis Services In Viet Nam And The Philippines (10:20 – 10:30) + Q&A (10:30 – 10:35)

Bethany Holt

The Time Interval From Diagnosis Of Chronic Hepatitis B To Initiation Of Antiviral Therapy And Its Association With Adherence To Treatment In The Gambia (10:35 – 10:45) + Q&A (10:45 – 10:50)

Zakary Warsop

Late-Breaker Abstracts Session

(16:30 - 18:30)

Moderators:

Late-breaker abstract: Depletion Of Dipeptidyl Peptidase 9 (Dpp9) In Hepatocytes Increases Beclin-1 And Activated Caspase-1 Protein Levels In An Experimental Model Of Hepatocellular Carcinoma (16:30 – 16:40) + Q&A (16:40 – 16:45)

Mark D Gorrell

Late-breaker abstract: Preclinical Antiviral Profiling Of Ab-161, An Oral Hbv Inhibitor That Destabilizes Hbv Rna And Suppresses Hbsag (16:45 – 16:55) + Q&A (16:55 – 17:00)

Angela M Lam

Late-breaker abstract: Efficacy And Safety Of Talen®-Mediated Genome Editing Of The Hepatitis B Virus Cccdna And Integrated Dna In Vivo (17:00 – 17:10) + Q&A (17:10 – 17:15)

Ramon Diaz Trelles

Late-breaker abstract: Are Hepatitis C Virus Core And Ns5a Polyamorous? Host Interacting Partners Identified In An Infection System (17:15 – 17:25) + Q&A (17:25 – 17:30)

Angeliki Anna Beka

Late-breaker abstract: Hepatitis Elimination In Context Of Pandemic Preparedness And Response – Opportunities To Strengthen Health Systems (17:30 – 17:40) + Q&A (17:40 – 17:45)

Nida Ali

Late-breaker abstract: The Impact Of Covid-19 Outbreak On The Elimination Of Hepatitis C In Taiwan (17:45 – 17:55) + Q&A (17:55 – 18:00)

Wen-Wen Yang

Late-breaker abstract: Real-Time Monitoring System For The Progress Of Hepatitis C Elimination: The Experience From Taiwan National Hepatitis C Elimination Progress Monitoring Information Network (Twnhcp-Min) (18:00 – 18:10) + Q&A (18:10 – 18:15)

Wen-Wen Yang

Late-breaker abstract: Update On The Hepatitis C Care Cascade And Progress Toward Hepatitis C Elimination In The United States In 2021 (18:15 – 18:25) + Q&A (18:25 – 18:30)

TUESDAY, APRIL 25, 2023

12:15 - 13:15 - INDUSTRY LUNCH SYMPOSIUM

Presented by

Title: GSK Looking to the future of hepatitis B: Why should we aim for functional cure?

Join our esteemed panel of experts to explore the real-world unmet needs for people living with chronic hepatitis B and understand the potential impact the advent of functional cure could have at the level of everyday patient care.

Speakers: 

Danjuma Adda is a Hepatitis B patient, advocate and a voice for poor populations. He was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later. He has a background in microbiology, and an MPH, with over 15 years-experience in public health and advocacy. Danjuma in 2021 assumed the role of President, World Hepatitis Alliance (WHA), UK. His local charity in Nigeria also works in the area of HIV/AIDS prevention and care, patient safety and antimicrobial resistance and stewardship in Nigeria, working to raise awareness and health care worker’s education to reduce the burden of antimicrobial resistance in Nigeria. Danjuma is a Senior Fellow with ASPEN Institute, US; Technical Advisor/Member of the World Health Organizations (WHO) Strategic and Advisory Committee on HIV, Viral Hepatitis and STIs (STAC-HHS); Executive Board Member Coalition for Global Hepatitis Elimination (CGHE) at the Global Task Force for Hepatitis US CDC; Member AMR Advisory Group of the AMR Patient Alliance; and member of several global networking groups and an accomplished Public Speaker. Danjuma is a leading voice for Hepatitis patients in Nigeria and uses his platform to advocate for the most vulnerable populations across Africa. Danjuma wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease, while also promoting other health outcomes such as antimicrobial stewardship and patient safety.

Dr Chari Cohen is President of the Hepatitis B Foundation. For the past 22 years, she has planned, implemented and evaluated community programs and research projects focusing on reducing health disparities and improving health outcomes associated with hepatitis B and liver cancer. Dr. Cohen is co-chair of the national Hep B United coalition, co-founder and chair of Hep B United Philadelphia, co-founder and chair of CHIPO: Coalition Against Hepatitis for People of African Origin; co-chair of the Hep Free PA coalition; and chair of the Sidney Kimmel Cancer Center Community Advisory Board. She is a member of the ICE-HBV steering committee, the HepVu advisory committee, and is a member of the HBV Forum for Collaborative Research and the Patient Advocacy Group of the American Association for the Study of Liver Diseases (AASLD). Dr. Cohen is Professor at the Baruch S. Blumberg Institute, and adjunct faculty for Geisinger Commonwealth School of Medicine. She received her DrPH in Community Health and Prevention from Drexel University and her MPH from Temple University.

Dr Ahmed El Sharkawy has been a consultant transplant hepatologist at the Queen Elizabeth Hospital in Birmingham since 2012. He is also honorary senior lecturer at the University of Birmingham and a Fellow of the Royal College of Physicians of London. His clinical interests include viral hepatitis, liver transplantation, polycystic liver disease, drug induced liver injury, primary biliary cholangitis, acute liver failure, acute on chronic liver failure, NAFLD (especially in the context of hepatitis B) and cirrhotic sarcopaenia. He has pioneered novel approaches to the management of hepatitis C in the community. He was awarded his PhD from Newcastle University on the role of NF-kB in the hepatic inflammation-fibrosis-cancer axis. He is a research active NHS clinician and is PI on a number of trials including a NIHR Liver Research Partnership on HBV Patient Engagement. He is the EASL Internal Affairs Councillor, Treasurer of BASL and Clinical Lead of the BASL HBV SiG. He is keen on promoting the role of social media, in particular Twitter, in medical education.

Professor Victor de Lédinghen MD PhD is Professor of Hepatology and is currently Head of the Hepatology and Liver Transplantation Unit, Haut Lévêque Hospital, University Hospital of Bordeaux, Pessac, France. Victor de Lédinghen graduated at Bordeaux University, and Cornell University (New York, USA) with a Hepato-Gastroenterology Degree and Medical Degree in 1993, and PhD in 2001. In 2003, he became Professor in Hepatology at the University Hospital of Bordeaux, France. Professor de Lédinghen has a long-standing interest in the non-invasive diagnosis of liver fibrosis and chronic liver diseases, and runs a clinical research programme studying the natural history of liver fibrosis, its impact upon patients and novel therapies for chronic liver diseases associated with liver fibrosis. His hepatology unit is the reference centre for all rare chronic liver diseases (PBC, PSC, Wilson’s disease…) in Nouvelle-Aquitaine (France). He supervises the clinical research programme of new drugs for nonalcoholic steatohepatitis (NASH) and HBV/HDV infection. His research has included participation in national and international HBV, HCV and NAFLD clinical trials, and had led to the publication of more than 300 articles in peer-reviewed journals. He supervises HBV HCV elimination in a large project “Bordeaux Metropolis without viral hepatitis”. He is a member of the European Association for the Study of the Liver, and the American Association for the Study of Liver Diseases. He is former Secretary General of the French Association for the Study of Liver Diseases (AFEF)

Associate Professor Thomas Tu is a molecular biologist and leads a research group at the Westmead Institute for Medical Research in the Storr Liver Centre (Sydney, Australia), where his team focuses on persistent forms of the Hepatitis B virus (covalently closed circular DNA and integrated HBV DNA) and develops methods to measure and eliminate them. He is particularly passionate about developing an HBV cure and mitigating the associated liver cancer, as he himself lives with chronic Hepatitis B. This provides him with unique perspectives on the disease as a researcher, patient, and advocate. He has won multiple awards for his research and outreach, most recently the 2022 Young Tall Poppy Science award. A/Prof Tu is President of the Australian Centre for Hepatitis Virology, the premier Australian society for hepatitis virus researchers. He is also the founder and Director of HepBCommunity.org (a global support network for people affected with HBV), guiding people through their HBV diagnosis, and linking them with trustworthy scientific and medical information. Recently he has established Hepatitis B Voices Australia, an advocacy group run by the affected community.

Date and Time: Tuesday, April 25  12:15 – 13:15

Location: Grand Ballroom 1

ANRS-AFEF Joint Symposium

The French model (8:30 - 10:30)

Moderators:

Fabrice Carrat

Marc Bourlière

France

The French HBV cohort from Hepather and beyond
(8:30 – 9:00)

Marc Bourlière

France

Extra-hepatic events following DAA treatment in patients with chronic hepatitis C: insights from the Hepather cohort linked with ‘Système National des Données de Santé’ medico-administrative data
(9:00 – 9:30)

Fabrice Carrat

HCC findings through the French Cohorts (9:30 – 10:00)

Panel discussion (10:00 – 10:30)

Symposium pré meeting AFEF/ANRS

10:30 - 12:30

Moderators:

Session CHC

Restitution recommandations AFEF cholangioK
(10:30 – 11:00)

Cindy Neuzillet

France

Cohorte française CHIEF : premiers résultats (11:00 – 11:20)

Eric Nguyen Khac

France

L’immunothérapie dans le CHC en 2023 et après (11:20 – 11:50)

Thomas Decaens

France

Session Hépatites virales

VHD : Résultats cohorte ANRS Buledelta (11:50 – 12:10)

Reflex testing VHB-VHD (12:10 – 12:30)

Véronique Loustaud Ratti

France

PLENARY 4

Global Hepatitis Summit 2023 Debrief (11:00 - 13:00)

Moderators:

HCV Debrief (11:00 – 11:25) + Q&A (11:25 – 11:30)

HBV/HDV Debrief (11:30 – 11:55) + Q&A (11:55 – 12:00)

NAFLD/NASH Debrief (12:00 – 12:25) + Q&A (12:25 – 12:30)

HCC Debrief (12:30 – 12:55) + Q&A (12:55 – 13:00)

Massimo Levrero

INSERM U1052 France

Clinical 6

Long-term outcomes of treated patients with viral hepatitis (8:30 - 10:05)

Moderators:

Long-term outcomes of treated HBV patients (8:30 – 8:50) + Q&A (8:50 – 8:55)

Long-term outcomes of cured HCV patients (8:55 – 9:15) + Q&A (9:15 – 9:20)

Effect Of Anti-Cd38 Monoclonal Antibodies On Hepatitis C Virus Replication In Chronically Infected Patients With Multiple Myeloma: A Prospective Series (9:20 – 9:30) + Q&A (9:30 – 9:35)

Harrys A. Torres

Evaluating Differences In On-Treatment Risk Of Hepatocellular Carcinoma Among A Large Cohort Of Predominantly Non-Asian Patients With Non-Cirrhotic Chronic Hepatitis B Infection (9:35 – 9:45) + Q&A (9:45 – 9:50)

Robert Wong

Long Term Follow Up Outcome Of Children Treated With Pegylated Interferon For Hbeag Reactive Chronic Hepatitis B (9:50 – 10:00) + Q&A (10:00 – 10:05)

Bikrant Biharilal Raghuvanshi

Clinical 5

New HDV therapies (8:30 - 10:35)

Moderators:

Maurizia Brunetto

Italy

Raymundo Parana

Brazil

Bulevirtide in HDV therapy (8:30 – 8:50) + Q&A (8:50 – 8:55)

Heiner Wedemeyer

Hannover Medical School Germany

New treatments in HDV (except bulevirtide) (8:55 – 9:15) + Q&A (9:15 – 9:20)

Pietro Lampertico

Italy

Bulevirtide Treatment For Hepatitis D In Decompensated Liver Disease – Clinical Experience Based On Real-World Case Reports (9:20 – 9:30) + Q&A (9:30 – 9:35)

Christopher Dietz-Fricke

Rescue Of Cirrhotic Chronic Hbv / Hdv Infection From Bulevirtide Failure By Subcutaneous Rep 2139-Mg (9:35 – 9:45) + Q&A (9:45 – 9:50)

Marc Bourlière

France

Safety And Efficacy Of Rep 2139-Mg In Association With Tdf In Patients With Chronic Hepatitis Delta And Decompensated Cirrhosis (9:50 – 10:00) + Q&A (10:00 – 10:05)

Christiane Stern

Late-breaker abstract: No Resistance Detected To Bulevirtide Monotherapy In Participants With Chronic Hepatitis D Through 24 Weeks Of Treatment From Phase Ii And Phase Iii Clinical Trials
(10:05 – 10:15) + Q&A (10:15 – 10:20)

Julius Hollnberger

Late-breaker abstract: Extended Follow-Up In The Rep 301 And Rep 401 Studies Demonstrates Durable Clinical Benefit From Nap Therapy
(10:20 – 10:30) + Q&A (10:30 – 10:35)

Andrew Vaillant

Clinical 8

Impacts of COVID-19 on liver disease management (16:30 - 18:35)

Moderators:

Negative impacts of COVID-19 on liver disease management (16:30 – 16:50) + Q&A (16:50 – 16:55)

Geoffrey Dusheiko

UK

Positive impacts of COVID-19 on liver disease management (16:55 – 17:15) + Q&A (17:15 – 17:20)

Clinical Characteristics Of Patients With Sars-Cov-2 Infection And Pre-Existing Chronic Liver Disease (17:20 – 17:30) + Q&A (17:30 – 17:35)

Sahar Hamza

Impact Of Telemedicine Access To Hepatitis C Specialty Care On The Cascade Of Care: A Retrospective Cohort Study (17:35 – 17:45) + Q&A (17:45 – 17:50)

Jui-Hsia Cleo Hung

Hcv Micro-Elimination In Msm In Germany: Impact Of Directly Acting-Antivirals And Behavior Change Due To The Covid 19 Pandemic (17:50 – 18:00) + Q&A (18:00 – 18:05)

Patrick Ingiliz

Trend Of Timely Hepatitis B Birth Dose Vaccine Coverage In The Gambia And Impact Of The Covid-19 Pandemic (18:05 – 18:15) + Q&A (18:15 – 18:20)

Gibril Ndow

Infant Hepatitis B Vaccination In Africa: Urgent Need To Support Infant Hepatitis B Vaccination Including Birth Dose Vaccine In Africa (18:20 – 18:30) + Q&A (18:30 – 18:35)

Neil Gupta

Basic 9

Liver inflammation and fibrogenesis (8:30 - 9:50)

Moderators:

François Dufour

Switzerland

Mathias Heikenwalder

Germany

Mechanisms of NAFLD/NASH-associated liver inflammation (8:30 – 8:50) + Q&A (8:50 – 8:55) 

Mechanisms of liver fibrogenesis (8:55 – 9:15) + Q&A (9:15 – 9:20)

Fabio Marra

Italy

Gene Expression Analysis Of Diseased And Control Liver Tissue To Explore Pathogenic Pathways In Inflammation (9:20 – 9:30) + Q&A (9:30 – 9:35)

Michael Stephanou

Auto-Aggressive Cd8 T Cells Represent Common Effectors Of Liver Damage Across Stages Of Chronic Hepatitis B (9:35 – 9:45) + Q&A (9:45 – 9:50)

Clinical 10

Viral hepatitis and liver transplantation in 2023 (16:30 - 17:50)

Moderators:

Sabela Lens

Spain

HCV and liver transplantation: 2023 update (16:30 – 16:50) + Q&A (16:50 – 16:55)

HBV/HDV and liver transplantation: 2023 update (16:55 – 17:15) + Q&A (17:15 – 17:20)

Treatment Of Patients With Hepatitis C After Liver Transplantation: Eight Years Of Real-Life Experience From The Centre Hospitalier De L’universite De Montreal (17:20 – 17:30) + Q&A (17:30 – 17:35)

Isaac Ruiz

Implementation Of The ‘Toronto Protocol’ Glecaprevir/Pibrentasvir+Ezetimibe, For Solid Organ Transplantation From Hcv Nat+ Donors To Hcv-Uninfected Recipients: Moving From Research To Standard Of Care (17:35 – 17:45) + Q&A (17:45 – 17:50)

Basic 8

HEV virology and persistence (16:30 - 18:50)

Moderators:

Ralf Bartenschlager

Germany

Heiner Wedemeyer

Hannover Medical School Germany

Update on HEV virology (16:30 – 16:50) + Q&A (16:50 – 16:55)

Mechanisms of HEV persistance in immunodepressed patients (16:55 – 17:15) + Q&A (17:15 – 17:20)

The Phosphatidylserine Receptor T-Cell Immunoglobulin Mucin Receptor 1 (Tim1) Mediates The Infection Of Enveloped Hepatitis E Virus (17:20 – 17:30) + Q&A (17:30 – 17:35)

Laura Corneillie

The Hepatitis E Virus Infectious Cycle – An Update (17:35 – 17:45) + Q&A (17:45 – 17:50) 

Zongdi Feng

Characterisation Of A Cell Culture System Of Persistent Hepatitis E Virus Infection In The Human Heparg Hepatic Cell Line (17:50 – 18:00) + Q&A (18:00 – 18:05)

Virginie Doceul

Oxysterol Binding Protein (Osbp) Is Needed For Hepatitis E Virus Replication In Cultured Hcellsepatoma Cells (18:05 – 18:15) + Q&A (18:15 – 18:20)

Yanjin Zhang

A Novel Class Of Glycan-Sensitive Human Monoclonal Antibodies Neutralising The Hepatitis E Virus (Hev) (18:20 – 18:30) + Q&A (18:30 – 18:35)

Katja Dinkelborg

Limited Impact On The Functions Of Nf-Κb Essential Modulator (Nemo) In Hepatitis A Virus-Infected Hepatocytes (18:35 – 18:45) + Q&A (18:45 – 18:50)

Hao-En Huang

NoHep Medical Visionaries Symposium

(16:30 - 18:30)

Moderators:

Olufunmilayo Lesi

Nigeria

Su Wang

USA

Lessons learned from HCV medication access and how to prepare for HBV cure (16:30 – 16:45) + Q&A (16:45 – 16:50)

Charles Gore

Challenges and solutions in Africa: Role of decentralization and community based care (16:50 – 17:05) + Q&A (17:05 – 17:10)

Endemic country leadership, a key component of HCV elimination efforts (17:10 – 17:25) + Q&A (17:25 – 17:30)

Isabela Ribeiro

Drugs for Neglected Diseases initiative - DNDi Switzerland

Long term injectable therapies for HBV/HCV (17:30 – 17:45) + Q&A (17:45 – 17:50)

Stigma in HBV/HCV as real barriers to care (17:50 – 18:05) + Q&A (18:05 – 18:10)

Discussion (18:10 – 18:30)

Debate 2

Clinical (14:00 - 16:00)

Chairs:

Maria Buti

Spain

Heiner Wedemeyer

Hannover Medical School Germany

Revisiting HBV treatment guidelines: a 2023 update (14:00 – 14:30)

Understanding HBV biomarkers, redifining new treatment endpoints (14:30 – 15:00)

The path forward in NAFLD/NASH therapeutic developments (15:00 – 15:30)

Vlad Ratziu

France

Classification of HCC patients for therapy (15:30 – 16:00)

Massimo Levrero

INSERM U1052 France

Public Health 3

Viral hepatitis elimination achievements and challenges (14:00 - 16:20)

Moderators:

Mojca Maticic

Slovenia

Global viral hepatitis elimination achievements (14:00 – 14:20) + Q&A (14:20 – 14:25)

Global viral hepatitis elimination challenges (14:25 – 14:45) + Q&A (14:45 – 14:50) 

Gregory Dore

Australia

Eliminating Hepatitis C In Australia: Success Through Workforce And Health Service Delivery Innovation (14:50 – 15:00) + Q&A (15:00 – 15:05)

Joseph Doyle

Achieving Micro-Elimination Of Hepatitis C Hyperendemic Aboriginal Townships In Taiwan: A Successful Model (15:05 – 15:15) + Q&A (15:15 – 15:20)

Chia-Yen Dai

The Community Pop-Up Clinic (Cpc): A Unique Strategy To Engage The Inner City In Hcv Elimination – And More (15:20 – 15:30) + Q&A (15:30 – 15:35)

Brian Conway

Gilead Liver Commitment And Local Elimination Programs Leading To Global Action In Hcv(Lega-C) : The Outcome And Impact From Late Phase Studies (15:35 – 15:45) + Q&A (15:45 – 15:50)

Kyung Min Kwon

Eliminating Hepatitis B: Anticipating Community And Public Health Implications For Any Hepatitis B Curative Interventions (15:50 – 16:00) + Q&A (16:00 – 16:05)

Jack Wallace

Unequal Access To Hbv Diagnostics In Resource Limited Settings Can Hinder Progress Towards The Who 2030 Viral Hepatitis Elimination Targets: International Coalition To Eliminate Hepatitis B Virus (Ice-Hbv) Survey Results (16:05 – 16:15) + Q&A (16:15 – 16:20)

Camila A Picchio

Basic 3

HBV/HDV virology (14:00 - 16:05)

Moderators:

Update on HBV virology (14:00 – 14:20) + Q&A (14:20 – 14:25)

Update on HDV virology (14:25 – 14:45) + Q&A (14:45 – 14:50)

Rxr-Mediated Regulation Of Surface Ntcp Expression And Its Effect On Ntcp-Medated Hepatitis B And Hepatitis D Virus Entry (14:50 – 15:00) + Q&A (15:00 – 15:05)

Hussein H. Aly

Hira Supports Hepatitis B Virus Minichromosome Establishment And Transcriptional Activity In Infected Hepatocytes (15:05 – 15:15) + Q&A (15:15 – 15:20)

Identification And Characterization Of Janus Kinase Jak1 As An Hdv-Related Host Factor And Antiviral Target (15:20 – 15:30) + Q&A (15:30 – 15:35)

Margaux Julie Heuschkel

Single Cell Resolved Analysis Of The Innate Immune Response Of Hdv Infected Stem Cell Derived Hepatocytes (15:35 – 15:45) + Q&A (15:45 – 15:50)

Arnaud Carpentier

Late-breaker abstract: Towards The Structural Characterization Of The Hepatitis Delta Virus Ribonucleoprotein Complex By Nmr
(15:50 – 16:00) + Q&A (16:00 – 16:05)

Yang Yang

Clinical 9

Hepatocellular carcinoma new drug clinical trial (14:15 - 15:05)

Moderators:

Nobuyuki Enomoto

Japan

Jean-Charles Nault

Avicenne Hospital, APHP France

HCC new drug clinical trials in Europe and North America (14:15 – 14:35) + Q&A (14:35 – 14:40)

HCC new drug clinical trials in Asia (14:40 – 15:00) + Q&A (15:00 – 15:05)

PLENARY 3

New vaccine approaches for liver diseases (11:00 - 13:00)

Moderators:

Michael Manns

Germany

Lessons from SARS-CoV-2 vaccination and boosting in non-human primates (11:00 – 11:25) + Q&A (11:25 – 11:30) 

Towards an HCV vaccine (11:30 – 11:55) + Q&A (11:55 – 12:00)

The future of therapeutic vaccines for viral infections (12:00 – 12:25) + Q&A (12:25 – 12:30)

Implementing global vaccination strategies (12:30 – 12:55) + Q&A (12:55 – 13:00)

SIGN ME UP FOR UPDATES

Margaret Hellard

Deputy Director Burnet Institute

Professor Margaret Hellard AM is a Deputy Director at the Burnet Institute, Head of Hepatitis Services in Department of Infectious Diseases at The Alfred Hospital and an Adjunct Professor at Monash University and University of Melbourne, Melbourne, Australia. Margaret is an infectious disease physician, public health physician and infectious diseases epidemiologist (and yes was one prior to COVID), with her work focusing on the management of blood borne viruses; the ultimate aim being to eliminate viral hepatitis as a public health threat and end the HIV/AIDS epidemic. A key aspect of this work is to ensure equity of access to all people at risk of blood borne viruses, including people who inject drugs. Since the COVID pandemic, Margaret has continued her blood borne virus work, whilst also undertaking modelling, public health and epidemiology studies aimed at reducing the direct and indirect impacts of the COVID-19 epidemic on the community. Again a focus is ensuring health and social equity for groups at greater risk of COVID infections and the public health responses aimed at reducing COVID. Margaret is a member of numerous advisory committees and working groups on viral hepatitis and HIV within Australia and globally, including Co-Chairing the WHO Strategi